Highlights Awakn Life Sciences Corp.

Equities

AWKN

CA05455W1086

Market Closed - Canadian Securities Exchange Other stock markets 12:12:10 08/05/2024 am IST			5-day change	1st Jan Change
0.195 ^CAD	-7.14%		0.00%	+34.48%

03/04	Awakn Life Sciences Corp. Announces Launch of Licensing Partnership Agreement with Rivus Wellness and Research Institute	CI
03/04	Awakn Life Sciences Corp. announced that it expects to receive CAD 1 million in funding	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Awakn Life Sciences Corp. Announces Launch of Licensing Partnership Agreement with Rivus Wellness and Research Institute	03/04	CI
Awakn Life Sciences Corp. Designates Program AWKN-002 for Alcohol Use Disorder in the US Market	24/01	CI
Awakn Life Sciences Corp. Enters Global Licensing Agreement with LTS Lohmann Therapie-Systeme AG	20/12	CI
Awakn Life Sciences Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended October 31, 2023	15/12	CI
Awakn Life Sciences Corp. Receives Clinical Trial Authorization from the Medicines and Healthcare Products Regulatory Agency and Health Research Authority in the UK for a Phase III Clinical Trial for its Lead Program AWKN-P001 for the Treatment of Severe Alcohol Use Disorder	15/11	CI
Awakn Life Sciences Completes MDMA Zydis(R) ODT Feasibility Study	04/23/04	CI
Awakn Life Sciences Corp. Reports Earnings Results for the Second Quarter and Six Months Ended July 31, 2023	14/23/14	CI
Awakn Life Sciences Submits Clinical Trial Application for Phase III Trial of AWKN-P001	06/23/06	CI
The management acquired Awakn Clinics Trondheim and Awakn Clinics Oslo from Awakn Life Sciences Corp..	01/23/01	CI
Awakn Via Amitis Ltd acquired Awakn London Limited from Awakn Life Sciences Corp..	05/23/05	CI
Awakn Life Sciences Corp. Reports Earnings Results for the First Quarter Ended April 30, 2023	15/23/15	CI
Awakn Life Sciences Corp. Reports Earnings Results for the Full Year Ended January 31, 2023	28/23/28	CI
Awakn Life Sciences Corp. Signs Collaboration Agreement with University of Exeter for Upcoming Phase Iii Trial	18/23/18	CI
Awakn Life Sciences Corp. Signs Its Fourth Licensing Partnership Agreement with Ken Starr MD Wellness Group	28/23/28	CI
Awakn Life Sciences Corp. Signs its First Licensing Partnership Agreement in Europe	21/23/21	CI
Awakn Life Sciences Corp. Announces the Opening of Its Fourth Clinic	14/23/14	CI
Awakn Life Sciences Initiates Feasibility Study for Mdma Using Catalent's Zydis Orally Disintegrating Tablet Technology	09/23/09	CI
Awakn Life Sciences Corp. Grants Fast-Track Designation from Uk Regulator for Ketamine-Assisted Therapy for Alcohol Use Disorder	07/23/07	CI
Awakn Life Sciences Initiates Investigative Study of Novel Formulation of (S)-Ketamine to Assess Dissociative Effect	24/23/24	CI
Awakn Life Sciences Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended October 31, 2022	15/22/15	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Awakn Life Sciences Corp.

Equities

AWKN

CA05455W1086

Highlights

Filters